|
== Investigación ==
LikeIgual manyque othermoitos growthoutros factorsfactores thatde havecrecemento beenque linked toforon diseaseasociados a enfermidades, o PDGF ande itsos receptorsseus havereceptores providedorixinaron aun marketmercado forpara [[antagonista de receptor|antagonistas antagonistde receptores]]s topara treattratar diseasediversas doenzas. SuchEntre antagonistsestes includeantagonistas (butestán, areentre not limited to) specificoutros, [[antibody|antibodiesanticorpo]]s thatespecíficos targetque theteñen [[molecule]]como ofdiana interesta molécula de interese, whichos actcales onlyactúan insó ade neutralizingmodo mannerneutralizante.<ref name="pmid9211881">{{cite journal |vauthors=Shulman T, Sauer FG, Jackman RM, Chang CN, Landolfi NF | title = An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization | journal = J. Biol. Chem. | volume = 272 | issue = 28 | pages = 17400–4 | date = July 1997 | pmid = 9211881 | doi = 10.1074/jbc.272.28.17400 | url = }}</ref>
TheO [[oncoxene]] "c-Sis" [[oncogene]] is derivedderiva fromdo ''PDGF''.<ref name="ReferenceA"/><ref>{{cite journal |vauthors=McClintock JT, Chan IJ, Thaker SR, Katial A, Taub FE, Aotaki-Keen AE, Hjelmeland LM | title = Detection of c-sis proto-oncogene transcripts by direct enzyme-labeled cDNA probes and in situ hybridization | journal = In Vitro Cell Dev Biol | volume = 28A | issue = 2 | pages = 102–8 | year = 1992 | pmid = 1537750 | doi = 10.1007/BF02631013 }}</ref>
AgeA relatedregulación downregulationá ofbaixa therelacionada PDGFcoa idade do receptor onde isletPDGF nas células beta cellsdos hasillotes beenpancreáticos demonstratedimpide toa preventproliferación isletde células beta celldos proliferationillotes intanto bothen animalcélulas andanimais humancoma cellshumanas ande itsa re-expressionsúa triggeredreexpresión desencadea a proliferación de células beta celle corrixe a regulación proliferationda andglicosa correctedpor glucosemedio regulationda via[[secereción]] insulinde secretion[[insulina]].<ref>{{cite web|url=http://www.eurekalert.org/pub_releases/2011-10/jdrf-rmo101211.php |title=Researchers make older beta cells act young again |publisher=Eurekalert.org |date=2011-10-12 |accessdate=2013-12-28}}</ref><ref>{{cite web |url=http://med.stanford.edu/ism/2011/october/kim.html |title=New Stanford molecular target for diabetes treatment discovered - Office of Communications & Public Affairs - Stanford University School of Medicine |publisher=Med.stanford.edu |date=2011-10-12 |accessdate=2013-12-28 |deadurl=yes |archiveurl=https://web.archive.org/web/20131021184626/http://med.stanford.edu/ism/2011/october/kim.html |archivedate=2013-10-21 |df= }}</ref>
A non-viral PDGF "bio patch" can regenerate missing or damaged bone by delivering DNA in a nano-sized particle directly into cells via genes. Repairing bone fractures, fixing craniofacial defects and improving dental implants are among potential uses. The patch employs a collagen platform seeded with particles containing the genes needed for producing bone. In experiments, it new bone fully covered skull wounds in test animals and stimulated growth in human bone marrow [[stromal cell]]s.<ref>{{cite web|url=http://www.kurzweilai.net/bio-patch-can-regrow-bone-for-dental-implants-and-craniofacial-defects |title=Bio patch can regrow bone for dental implants and craniofacial defects |doi=10.1016/j.biomaterials.2013.10.021 |publisher=KurzweilAI |date=2013-11-12 |accessdate=2013-12-28}}</ref><ref>{{cite journal |vauthors=Elangovan S, D'Mello SR, Hong L, Ross RD, Allamargot C, Dawson DV, Stanford CM, Johnson GK, Sumner DR, Salem AK | title = The enhancement of bone regeneration by gene activated matrix encoding for platelet derived growth factor | journal = Biomaterials | volume = 35 | issue = 2 | pages = 737–747 | year = 2014 | pmid = 24161167 | pmc = 3855224 | doi = 10.1016/j.biomaterials.2013.10.021 }}</ref>
|
